Patrys Adds Global Experts as RLS-2202 Enters Delirium Trial Planning
Patrys has formed an international Clinical Advisory Committee to help shape the next stages of RLS-2202, its injectable quetiapine candidate for delirium in acute-care settings. The appointments add recognised expertise in delirium research, intensive care and trial design, but do not yet provide clinical efficacy or regulatory evidence.
- International advisory committee spans Australia, the United States and Europe
- RLS-2202 Phase 1 program is underway in healthy volunteers
- Committee to advise on patient selection, endpoints and future trial design
- Members bring experience in delirium guidelines, research and intensive-care practice
- No efficacy results, timelines or financial impact were disclosed
Global Delirium Expertise Added to RLS-2202 Program
Patrys Limited (ASX:PAB) has assembled an international clinical panel as its injectable quetiapine candidate RLS-2202 moves through Phase 1 and towards studies in patients with delirium. The Clinical Advisory Committee includes specialists from Australia, the United States and Europe, giving the company access to expertise across acute care, critical care, clinical guidelines and trial design.
The committee will advise on the issues that could determine whether later-stage studies are practical as well as scientifically credible: patient selection, clinically meaningful endpoints, trial structure and the realities of treating delirium in acute-care settings. Patrys also says the group will help connect the program with clinical centres and specialist networks.
Committee Links Trial Design With Intensive-Care Practice
Dr Johnny Iliff, an emergency physician at Royal Perth Hospital and St John of God Murdoch Hospital, will chair the committee and provide the Australian perspective. His remit includes assessing whether recommendations are feasible, safe and aligned with how delirium is managed in critically ill patients.
US member Professor John W. Devlin brings experience spanning antipsychotic research, ICU delirium, clinical guidelines and implementation across health systems. He chaired the Society of Critical Care Medicine’s 2018 PADIS guidelines, while European member Professor Mark van den Boogaard developed the E-PRE-DELIRIC delirium prediction model and has contributed to US and Dutch ICU guidelines.
Phase 1 Remains the Immediate Test
Patrys said its Phase 1 program in healthy volunteers is now underway, with planning beginning for subsequent clinical evaluation in patients with delirium. The advisory appointments may strengthen the framework around those future studies, particularly as the company considers different clinical, regulatory and health-system environments in its target jurisdictions.
That is useful development infrastructure, rather than evidence that RLS-2202 works. The announcement contains no safety, pharmacokinetic or efficacy results, patient-study timetable, participant numbers, regulatory approval or commercial terms. The next material marker will be what the Phase 1 program shows, followed by whether Patrys can translate the committee’s advice into a defined and credible patient trial.
Bottom Line?
The committee improves the program’s clinical depth, but the investment case still turns on Phase 1 evidence and the design of the first patient study.
Questions in the middle?
- When will Patrys disclose safety and pharmacokinetic findings from the Phase 1 program?
- What patient population, endpoint and trial design will be chosen for the first delirium study?
- Can RLS-2202 demonstrate a practical clinical advantage in the complex acute-care environment?
